WO2012128501A3 - 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물 - Google Patents

포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2012128501A3
WO2012128501A3 PCT/KR2012/001855 KR2012001855W WO2012128501A3 WO 2012128501 A3 WO2012128501 A3 WO 2012128501A3 KR 2012001855 W KR2012001855 W KR 2012001855W WO 2012128501 A3 WO2012128501 A3 WO 2012128501A3
Authority
WO
WIPO (PCT)
Prior art keywords
3m3fbs
preventing
diseases
inflammatory diseases
infectious diseases
Prior art date
Application number
PCT/KR2012/001855
Other languages
English (en)
French (fr)
Other versions
WO2012128501A2 (ko
WO2012128501A9 (ko
Inventor
배외식
김상두
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to US14/005,737 priority Critical patent/US9468616B2/en
Publication of WO2012128501A2 publication Critical patent/WO2012128501A2/ko
Publication of WO2012128501A3 publication Critical patent/WO2012128501A3/ko
Publication of WO2012128501A9 publication Critical patent/WO2012128501A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명의 목적은 m-3M3FBS 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 조성물을 제공함에 있다. 또한 본 발명의 또다른 목적은 m-3M3FBS을 포함하는 염증성 질환 또는 감염성 질환의 개선 또는 예방용 건강기능식품을 제공함에 있다. 본 발명의 m-3M3FBS는 살균효과, 세포사멸억제, LPS관여 신호전달을 억제하는 효과를 나타내는 바, 염증성 질환 또는 감염성 질환의 효과적인 치료 또는 예방을 가능하게 하므로 염증성 질환 또는 감염성 질환의 치료 또는 예방을 위한 의약품 또는 건강기능식품으로 유용하게 사용될 수 있다.
PCT/KR2012/001855 2011-03-18 2012-03-14 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물 WO2012128501A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/005,737 US9468616B2 (en) 2011-03-18 2012-03-14 Pharmaceutical composition for preventing or treating inflammatory diseases or infectious diseases, containing m-3M3FBS, which is activator of phospholipase C, as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110024239A KR101303991B1 (ko) 2011-03-18 2011-03-18 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물
KR10-2011-0024239 2011-03-18

Publications (3)

Publication Number Publication Date
WO2012128501A2 WO2012128501A2 (ko) 2012-09-27
WO2012128501A3 true WO2012128501A3 (ko) 2012-12-27
WO2012128501A9 WO2012128501A9 (ko) 2013-02-14

Family

ID=46879859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001855 WO2012128501A2 (ko) 2011-03-18 2012-03-14 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물

Country Status (3)

Country Link
US (1) US9468616B2 (ko)
KR (1) KR101303991B1 (ko)
WO (1) WO2012128501A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104548060B (zh) * 2014-12-19 2017-09-19 上海市肺科医院 化合物调节tak1活性的方法及该化合物用于治疗手足口病的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038976A1 (en) * 2002-05-24 2004-02-26 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20040220268A1 (en) * 2003-05-02 2004-11-04 Yoe-Sik Bae Compound that directly stimulates phospholipase C activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038976A1 (en) * 2002-05-24 2004-02-26 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20040220268A1 (en) * 2003-05-02 2004-11-04 Yoe-Sik Bae Compound that directly stimulates phospholipase C activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAE, YOE-SIK ET AL.: "Identification of a Compound That Directly Stimulates Phospholipase C Activity.", MOLECULAR PHARMACOLOGY, vol. 63, no. 5, 2003, pages 1043 - 1050 *
KIM, SANG DOO ET AL.: "Phospholipase C Activator m-3M3FBS Protects against Morbidity and Mortality Associated with Sepsis.", THE JOURNAL OF IMMUNOLOGY, vol. 189, 2012, pages 2000 - 2005 *
LEE, YOUL-NAM ET AL.: "The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis.", CANCER LETTERS., vol. 222, 2005, pages 227 - 235 *

Also Published As

Publication number Publication date
US9468616B2 (en) 2016-10-18
KR101303991B1 (ko) 2013-09-04
WO2012128501A2 (ko) 2012-09-27
US20140005271A1 (en) 2014-01-02
KR20120106248A (ko) 2012-09-26
WO2012128501A9 (ko) 2013-02-14

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12016501750A1 (en) Human plasma kallikrein inhibitors
NZ708593A (en) Novel pyrazole derivative
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014DN06501A (ko)
MX2014003080A (es) Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
PH12015502365A1 (en) Bace1 inhibitors
TN2012000458A1 (en) Uses of dgat1 inhibitors
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
MX2016004909A (es) Composicion que contiene eugenol como principio activo para prevenir o tratar la dermatitis atopica.
WO2011118957A3 (ko) 파프리카 추출물을 함유하는 염증, 알레르기 또는 천식 질환 치료용 조성물
PH12018500433A1 (en) Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
WO2012128501A3 (ko) 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761298

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14005737

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12761298

Country of ref document: EP

Kind code of ref document: A2